Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962483 | 0.82 | KDM4E (0.33) | ADORA2A | |
| SCHEMBL25034054 | 0.80 | ADORA1 (0.41) | — | |
| SCHEMBL22013613 | 0.79 | — | — | |
| SCHEMBL25033746 | 0.79 | KMT2A (0.37) | ADORA2AHTR6 | |
| SCHEMBL21962780 | 0.76 | KDM4E (0.32) | ADORA2A | |
| SCHEMBL22012058 | 0.71 | DRD2 (0.36) | DRD2HTR2AHTR2CDRD3HTR6 | |
| SCHEMBL25034052 | 0.70 | ADORA1 (0.40) | — | |
| SCHEMBL20692242 | 0.65 | DRD2 (0.47) | DRD2HTR2AHTR2CDRD3HTR6 | |
| SCHEMBL21962667 | 0.64 | WDR91 (0.35) | DRD2HTR2AHTR2CDRD3HTR6 | |
| SCHEMBL20692074 | 0.64 | DRD2 (0.46) | DRD2HTR2AHTR2CDRD3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ADORA2A 587/4885CHRM3 4211/4885DRD2 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.